These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16166962)

  • 21. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary.
    Lefebvre JL; Ang KK;
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1293-303. PubMed ID: 19306746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The hazards of intermediate endpoints.
    Beer TM; Ryan CW
    Cancer; 2007 Nov; 110(9):1877-9. PubMed ID: 17849427
    [No Abstract]   [Full Text] [Related]  

  • 23. Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary.
    Lefebvre JL; Ang KK;
    Head Neck; 2009 Apr; 31(4):429-41. PubMed ID: 19283793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are onsite image evaluations the solution or are we trading one problem for another?
    Raunig DL
    J Clin Oncol; 2009 Dec; 27(35):e263-4; author reply e265. PubMed ID: 19901131
    [No Abstract]   [Full Text] [Related]  

  • 25. The emperor's new clothes or the current practice of clinical trials for multiple myeloma in the USA.
    Ballester O
    Cancer Invest; 2008 Jun; 26(5):445-7. PubMed ID: 18568765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials.
    Collette L; Burzykowski T; Schröder FH
    Eur J Cancer; 2006 Jul; 42(10):1344-50. PubMed ID: 16730974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic therapy for metastatic urothelial carcinoma.
    Lin CC; Hsu CH; Pu YS; Vogelzang NJ
    BJU Int; 2008 Apr; 101(7):795-803. PubMed ID: 18070193
    [No Abstract]   [Full Text] [Related]  

  • 30. The clinical significance of statistical significance.
    Kane RC
    Oncologist; 2008 Nov; 13(11):1129-33. PubMed ID: 18984874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
    Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
    J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
    [No Abstract]   [Full Text] [Related]  

  • 32. Commentary on 'designing phase II studies in cancer with time-to-event endpoints'.
    Case D; Morgan T
    Clin Trials; 2008; 5(3):222-3; discussion 223-4. PubMed ID: 18559410
    [No Abstract]   [Full Text] [Related]  

  • 33. Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer.
    Halabi S
    Urol Oncol; 2008; 26(3):300-7. PubMed ID: 18452825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapse pattern of GOG 122 trial should be more informative.
    Ozyar E; Genc M
    J Clin Oncol; 2006 Aug; 24(22):3709-10; author reply 3710. PubMed ID: 16877741
    [No Abstract]   [Full Text] [Related]  

  • 36. Dealing with multiple endpoints.
    Dueck A; Novotny PJ
    Curr Probl Cancer; 2006; 30(6):298-306. PubMed ID: 17123881
    [No Abstract]   [Full Text] [Related]  

  • 37. A combined superiority and non-inferiority approach to multiple endpoints in clinical trials.
    Bloch DA; Lai TL; Su Z; Tubert-Bitter P
    Stat Med; 2007 Mar; 26(6):1193-207. PubMed ID: 16791905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions.
    Ganz PA; Gotay CC
    J Clin Oncol; 2007 Nov; 25(32):5063-9. PubMed ID: 17991922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemoradiotherapy in esophageal cancer: is it still the question?
    Pereira B; Gourgou-Bourgade S; Azria D; Ychou M
    J Clin Oncol; 2008 Nov; 26(31):5133-4; author reply 5134. PubMed ID: 18838699
    [No Abstract]   [Full Text] [Related]  

  • 40. Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years?
    Anderson E; Grant R; Lewis SC; Whittle IR
    Br J Neurosurg; 2008 Jun; 22(3):339-49. PubMed ID: 18568722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.